traded on nasdaq capital market, stock symbol eyeg, eyegate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“cmha-s”), a modified form of the natural polymer hyaluronic acid (“ha”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. our first cmha-s-based product candidate, the eyegate ocular bandage gel (“obg”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“prk”) surgery. our initial product candidate from our second platform is egp-437, incorporates a reformulated topically active corticosteroid, dexamethasone